We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -68.00 | -0.60% | 11,276.00 | 11,314.00 | 11,320.00 | 11,350.00 | 11,232.00 | 11,248.00 | 3,209,753 | 16:35:05 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 45.81B | 5.96B | 3.8406 | 29.47 | 175.89B |
From Feb 2020 to Feb 2025
By Rory Gallivan
LONDON--AstraZeneca PLC (AZN.LN) Friday announced positive results from a Phase III trial of its breast cancer treatment Lynparza.
Metastatic breast cancer patients treated with the drug "showed a statistically-significant and clinically-meaningful improvement" compared with patients who received chemotherapy, AstraZeneca said.
-Write to Rory Gallivan at rory.gallivan@wsj.com; Twitter: @RoryGallivan
(END) Dow Jones Newswires
February 17, 2017 02:30 ET (07:30 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
